Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 50Neoplasms 13Neoplasm Metastasis 12Gastrointestinal Stromal Tumors 10Carcinoma, Hepatocellular 7Glioblastoma 5Colonic Neoplasms 5Sarcoma 4Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Liver Neoplasms 3Rhabdomyosarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Advanced Cancer 2Wilms Tumor 1Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solid Tumor 1Sarcoma, Ewing 1

Interventions

regorafenib 1napabucasin 1Videotape Recording 1Patient Care Planning 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Gastrointestinal Cancer × regorafenib × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡